Cargando…

Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats

Puromycin aminonucleoside (PAN)-induced nephrosis is a well-described model of human idiopathic nephrotic syndrome, but the mechanism of PAN's effect is not completely understood. To investigate whether proteinuria in the PAN model is associated with an alteration of zonula occludens-1 (ZO-1) e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Beom Seok, Park, Hyeong Cheon, Kang, Shin Wook, Choi, Kyu Hun, Ha, Sung Kyu, Han, Dae Suk, Lee, Ho Yung
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823040/
https://www.ncbi.nlm.nih.gov/pubmed/15744817
http://dx.doi.org/10.3349/ymj.2005.46.1.141
_version_ 1782177589616443392
author Kim, Beom Seok
Park, Hyeong Cheon
Kang, Shin Wook
Choi, Kyu Hun
Ha, Sung Kyu
Han, Dae Suk
Lee, Ho Yung
author_facet Kim, Beom Seok
Park, Hyeong Cheon
Kang, Shin Wook
Choi, Kyu Hun
Ha, Sung Kyu
Han, Dae Suk
Lee, Ho Yung
author_sort Kim, Beom Seok
collection PubMed
description Puromycin aminonucleoside (PAN)-induced nephrosis is a well-described model of human idiopathic nephrotic syndrome, but the mechanism of PAN's effect is not completely understood. To investigate whether proteinuria in the PAN model is associated with an alteration of zonula occludens-1 (ZO-1) expression within the glomeruli, and whether cyclosporin A (CsA) has an effect on proteinuria and ZO-1 expression in this model, eighteen Sprague Dawley (SD) rats were assigned into three groups. Twelve rats received a single intraperitoneal injection of PAN (15 mg/100 g). The other six rats received an equal volume of saline (normal control group; control). CsA solution was administered intraperitoneally once a day for 20 days after the PAN injection (n=6, PAN+CsA). The remaining six rats received PAN, but they didn't receive CsA (n=6, PAN). Compared to control rats (35.1 ± 5.4 mg/day), the 24-hour urinary protein excretion on day 18 was significantly higher in the PAN rats (1021.9 ± 128.9 mg/day, p<0.01), and the CsA treatment partly reversed the increase in proteinuria in the PAN rats (556.4 ± 102.3 mg/day, p<0.05). Glomerular ZO-1 protein expressions were significantly increased in the PAN rats as compared to the control group on day 20 (176%, p<0.01). CsA treatment for 20 days in the PAN rats inhibited the increase in ZO-1 protein expression by 71.1% (p<0.05). CsA treatment significantly diminished the glomerular ZO-1 expression in the PAN rats as assessed by immunohistochemistry. CsA treatment significantly reduced proteinuria and the diminished glomerular ZO-1 expression in a PAN nephrosis rat model. These findings suggest the potential role of the slit diaphragm associated proteins in the development of the nephrotic syndrome, and CsA decreased the proteinuria probably by a direct action on the expression of these proteins in podocytes. Further investigations are needed to clarify the role of slit diaphragm associated proteins in the development of PAN nephrosis.
format Text
id pubmed-2823040
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-28230402010-02-17 Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats Kim, Beom Seok Park, Hyeong Cheon Kang, Shin Wook Choi, Kyu Hun Ha, Sung Kyu Han, Dae Suk Lee, Ho Yung Yonsei Med J Original Article Puromycin aminonucleoside (PAN)-induced nephrosis is a well-described model of human idiopathic nephrotic syndrome, but the mechanism of PAN's effect is not completely understood. To investigate whether proteinuria in the PAN model is associated with an alteration of zonula occludens-1 (ZO-1) expression within the glomeruli, and whether cyclosporin A (CsA) has an effect on proteinuria and ZO-1 expression in this model, eighteen Sprague Dawley (SD) rats were assigned into three groups. Twelve rats received a single intraperitoneal injection of PAN (15 mg/100 g). The other six rats received an equal volume of saline (normal control group; control). CsA solution was administered intraperitoneally once a day for 20 days after the PAN injection (n=6, PAN+CsA). The remaining six rats received PAN, but they didn't receive CsA (n=6, PAN). Compared to control rats (35.1 ± 5.4 mg/day), the 24-hour urinary protein excretion on day 18 was significantly higher in the PAN rats (1021.9 ± 128.9 mg/day, p<0.01), and the CsA treatment partly reversed the increase in proteinuria in the PAN rats (556.4 ± 102.3 mg/day, p<0.05). Glomerular ZO-1 protein expressions were significantly increased in the PAN rats as compared to the control group on day 20 (176%, p<0.01). CsA treatment for 20 days in the PAN rats inhibited the increase in ZO-1 protein expression by 71.1% (p<0.05). CsA treatment significantly diminished the glomerular ZO-1 expression in the PAN rats as assessed by immunohistochemistry. CsA treatment significantly reduced proteinuria and the diminished glomerular ZO-1 expression in a PAN nephrosis rat model. These findings suggest the potential role of the slit diaphragm associated proteins in the development of the nephrotic syndrome, and CsA decreased the proteinuria probably by a direct action on the expression of these proteins in podocytes. Further investigations are needed to clarify the role of slit diaphragm associated proteins in the development of PAN nephrosis. Yonsei University College of Medicine 2005-02-28 2005-02-28 /pmc/articles/PMC2823040/ /pubmed/15744817 http://dx.doi.org/10.3349/ymj.2005.46.1.141 Text en Copyright © 2005 The Yonsei University College of Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Beom Seok
Park, Hyeong Cheon
Kang, Shin Wook
Choi, Kyu Hun
Ha, Sung Kyu
Han, Dae Suk
Lee, Ho Yung
Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats
title Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats
title_full Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats
title_fullStr Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats
title_full_unstemmed Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats
title_short Impact of Cyclosporin on Podocyte ZO-1 Expression in Puromycin Aminonucleoside Nephrosis Rats
title_sort impact of cyclosporin on podocyte zo-1 expression in puromycin aminonucleoside nephrosis rats
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823040/
https://www.ncbi.nlm.nih.gov/pubmed/15744817
http://dx.doi.org/10.3349/ymj.2005.46.1.141
work_keys_str_mv AT kimbeomseok impactofcyclosporinonpodocytezo1expressioninpuromycinaminonucleosidenephrosisrats
AT parkhyeongcheon impactofcyclosporinonpodocytezo1expressioninpuromycinaminonucleosidenephrosisrats
AT kangshinwook impactofcyclosporinonpodocytezo1expressioninpuromycinaminonucleosidenephrosisrats
AT choikyuhun impactofcyclosporinonpodocytezo1expressioninpuromycinaminonucleosidenephrosisrats
AT hasungkyu impactofcyclosporinonpodocytezo1expressioninpuromycinaminonucleosidenephrosisrats
AT handaesuk impactofcyclosporinonpodocytezo1expressioninpuromycinaminonucleosidenephrosisrats
AT leehoyung impactofcyclosporinonpodocytezo1expressioninpuromycinaminonucleosidenephrosisrats